Avidity Biosciences Inc.

$RNA, a biopharmaceutical company focussed on a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced that it intends to offer $500.0 million of shares of its common stock in an underwritten public offering. In addition, they intend to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of common stock.